Show Notes
Chronic lymphocytic leukemia is the most common leukemia in adults, yet its earliest warning sign often hides in plain sight. Monoclonal B cell lymphocytosis, or MBL, affects millions of adults who may never know they carry this precursor to CLL. In this episode of Tomorrow's Cure from Mayo Clinic, host Cathy Wurzer talks with hematologist Dr. Sameer Parikh and researchers Dr. Susan Slager and Dr. Gerald Marti about how MBL was discovered, what it reveals about inherited risk, and why it matters for infections, second cancers and long term health.
The conversation explores how large population studies at Mayo Clinic, advanced genomics, and emerging tools like artificial intelligence and liquid biopsy could change when and how CLL is found, monitored and treated. Listeners will also hear candid discussion about ethics, anxiety and watchful waiting, and how Mayo Clinic's PreCure initiative is rethinking cancer prevention clinics for people living with early warning signs in their blood.
How to listen and stay connected:• Subscribe to Tomorrow’s Cure on your favorite podcast app and follow the show so you never miss an episode.• Get the latest health information from Mayo Clinic’s experts—subscribe to Mayo Clinic’s newsletter for free today: https://mayocl.in/3EcNPNc
Connect with Mayo Clinic:• Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/Follow • Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/Follow • Mayo Clinic on X (formerly Twitter): https://x.com/MayoClinicFollow • Mayo Clinic on Threads: https://www.threads.net/@mayoclinic
More from Tomorrow's Cure
How could Mayo Clinic’s Global AI Platform transform personalized care?
What if transplant patients could one day live free from lifelong anti-rejection drugs?
What happens when multiple sclerosis symptoms mask a different condition?
What if repairing damaged cartilage could be done in a single procedure? Using your own cells and the healing signals they need to recover?
What if the milk you are drinking could help fight cancer? In this episode of Tomorrow's Cure, we explore cholangiocarcinoma and a surprising new approach to targeting it using milk‑derived nanoparticles and precision aptamer‑based delivery. Host Lindsey Seavert is joined by surgical oncologist Dr. Rory Smoot and long‑term survivor and advocate Melinda Bachini to unpack why this cancer is so challenging, what symptoms and treatment paths patients typically face, and how emerging gene‑delivery platforms and AI‑driven discovery are opening new possibilities when standard therapies fall short. Through Melinda’s 16‑year survivorship story and Dr. Smoot’s lab work that literally starts with skim milk from the Mayo Clinic cafeteria, listeners hear how “chemical antibodies” called aptamers can act as molecular keys to deliver therapy directly to cholangiocarcinoma cells, and how computational tools are accelerating the search for new targets. Together, they discuss the emotional and practical realities of living at the edge of what medicine can do today, the expanding landscape of clinical trials, and why innovation in this rare cancer may ripple out to colon, lung and other hard‑to‑treat tumors.